A double-blind, placebo-controlled, crossover study of verapamil in exertional muscle pain.
Eleven patients, comprising three cases of McArdle's disease and eight with an exertional muscle pain syndrome (EMPS) of unknown cause, entered a double-blind crossover study of verapamil and placebo. None of the patients with McArdle's disease responded to verapamil, but two patients with unclassified EMPS experienced a striking improvement in symptoms and two others showed a partial response. No patient responded to placebo. Six of the eight cases with unclassified EMPS, including the four patients who responded to verapamil, had symptoms that indicated possible abnormalities of muscle metabolism, and four showed nonspecific biochemical, electromyographic, and muscle biopsy abnormalities. The two other EMPS patients had symptoms that suggested that a primary muscle disease was unlikely. They showed no laboratory evidence of muscle disorder, but had abnormal profiles on personality (MMPI) testing. Calcium antagonists, such as verapamil, may be useful in the treatment of some patients with benign exertional myalgia, but the mechanism of action of the drug in such cases is unclear.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006008:Glycogen Storage Disease / Q000188:drug therapy*; D006012:Glycogen Storage Disease Type V / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009135:Muscular Diseases / Q000175:diagnosis / Q000188:drug therapy*; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy*; D005082:Physical Exertion; D014700:Verapamil / Q000627:therapeutic use*
D014700:Verapamil